Khi Soldano, NP
Nurse Practitioner · Great Falls, MTNPI 1639582968
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AstraZeneca at 26.3% of the total. Reporting peaked in 2023 at $488 and has fallen 76.4% since, to $115 in 2025. Among nurse practitioner clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$250
- GSK$128
- E.r. Squibb & Sons, L.L.C.$67
- Astellas Pharma US Inc$65
- Amgen$62
- Novo Nordisk$55
- plus $324 from 12 others
What the payments were for
- Food & beverage$93999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $250 |
| GSK | 7 | $128 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Astellas Pharma US Inc | 3 | $65 |
| Amgen | 3 | $62 |
| Novo Nordisk | 3 | $55 |
| Pfizer | 4 | $52 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Novartis | 2 | $29 |
| Lilly USA, LLC | 2 | $27 |
| Merck | 2 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Verona Pharma, Inc. | 1 | $20 |
| UCB, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Exact Sciences | 1 | $14 |
How this compares
$951 in reported general payments places this provider in the 90th percentile of 357 nurse practitioner providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $119,458 |
| JanuviaSitagliptin Phosphate | 71 | $65,923 |
| EliquisApixaban | 37 | $42,182 |
| FarxigaDapagliflozin Propanediol | 31 | $38,083 |
| XareltoRivaroxaban | 27 | $22,623 |
| RybelsusSemaglutide | 11 | $15,463 |
| TrulicityDulaglutide | 13 | $14,129 |
| MyrbetriqMirabegron | 12 | $9,806 |
| LinzessLinaclotide | 15 | $8,655 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,579 |
| Levothyroxine Sodium | 376 | $3,650 |
| Atorvastatin Calcium | 445 | $3,357 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $2,610 |
| Pantoprazole Sodium | 149 | $2,508 |
| Rosuvastatin Calcium | 142 | $2,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $55 | $134,920110 claims |
| MerckJanuvia | $27 | $65,92371 claims |
| PfizerEliquis | $52 | $42,18237 claims |
| AstraZenecaFarxiga | $250 | $38,08331 claims |
| Lilly USA, LLCTrulicity | $27 | $14,12913 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $9,80612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 357 nurse practitioner providers in Montana.
Other nurse practitioner in Great Falls
- Bowen TrystiansonGreat Falls$6K
- Amber MolnarGreat Falls$4K
- Jessica BosoGreat Falls$4K
- Whitney McKinleyGreat Falls$3K
- Elizabeth O'ConnorGreat Falls$3K
- Vilma HerreraGreat Falls$2K
- Carrie PowellGreat Falls$2K
- Martin CamachoGreat Falls$1K
- Gina HansenGreat Falls$1K
- Melanie BrownGreat Falls$833
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.